- Exchange: NASDAQ GM
- Sector: Health Care
- Industry: Biotech & Pharma
- Sub-Industry: Specialty Pharmaceuticals
Cyclacel Pharmaceuticals Inc
+ Add to WatchlistCYCC:US
3.0900 USD 0.0300 0.96%As of 20:10:00 ET on 06/19/2013.
Snapshot for Cyclacel Pharmaceuticals Inc (CYCC)
| Open: | 3.1100 | Day's Range: | 3.0500 - 3.1200 | Volume: | 246,568 |
|---|---|---|---|---|---|
| Previous Close: | 3.1200 | 52wk Range: | 2.9100 - 8.1800 | 1-Yr Rtn: | -7.65% |
Key Statistics for CYCC
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (ttm) | -2.5200 |
| Est. EPS (12/2013) | - |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 54.74 |
| Shares Outstanding (M) | 17.72 |
| 30 Day Average Volume | 424,432 |
| Price/Book (mrq) | - |
| Price/Sale (ttm) | - |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/14/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for CYCC
Company Profile & Key Executives for CYCC
Cyclacel Pharmaceuticals Inc. discovers and develops small molecule cycle inhibitors for the treatment of cancer and other serious diseases.
| Spiro G RombotisPresident/CEO | Paul McBarronExec VP:Finance/CFO/COO/Secy |
| Judy ChiaoVP:Clinical Dev & Reg Affairs |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
CYCC News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page